FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037221770> ?p ?o ?g. }

• W2037221770 endingPage "67" @default.
• W2037221770 startingPage "61" @default.
• W2037221770 abstract "This study was an open-label multicenter phase II trial to investigate the efficacy and safety of nab-paclitaxel and bevacizumab as first-line therapy in patients with histologically confirmed unresectable metastatic melanoma.The treatment regimen consisted of a 28-day cycle in which patients received nab-paclitaxel, 150 mg/m through intravenous (IV) infusion weekly for 3 weeks and bevacizumab, 10 mg/kg IV every 2 weeks without a rest period. The 28-day cycle was repeated until there was unacceptable toxicity or disease progression. If 1 drug had to be stopped because of toxicity, treatment was continued with the other drug until disease progression or unacceptable toxicity. The primary endpoint was the progression-free survival rate (PFS) at 4 months.Fifty patients were enrolled. The PFS rate at 4 months was 75%. The median PFS was 7.6 months and the median overall survival was 16.8 months with a median duration follow-up of 41.6 months. The overall survival rate was 64% at 1 year and 30% at 2 years. Ten patients (20%) remain alive. The objective response rate was 36%. Common adverse events associated with this regimen were peripheral neuropathy, fatigue, alopecia, and gastrointestinal disorders.In this phase II multicenter study, this doublet had significant activity in patients with metastatic melanoma, and was well tolerated. These results are promising and follow-up trials to further explore this regimen are warranted." @default.
• W2037221770 created "2016-06-24" @default.
• W2037221770 creator A5005150991 @default.
• W2037221770 creator A5019015178 @default.
• W2037221770 creator A5028592995 @default.
• W2037221770 creator A5060495866 @default.
• W2037221770 creator A5073111231 @default.
• W2037221770 creator A5078388888 @default.
• W2037221770 creator A5088351796 @default.
• W2037221770 date "2015-02-01" @default.
• W2037221770 modified "2023-10-13" @default.
• W2037221770 title "Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma" @default.
• W2037221770 cites W1520571564 @default.
• W2037221770 cites W1602407234 @default.
• W2037221770 cites W1606837855 @default.
• W2037221770 cites W1879616740 @default.
• W2037221770 cites W1917632054 @default.
• W2037221770 cites W1919811975 @default.
• W2037221770 cites W1951046932 @default.
• W2037221770 cites W1966231228 @default.
• W2037221770 cites W1971211622 @default.
• W2037221770 cites W1981358533 @default.
• W2037221770 cites W1983984116 @default.
• W2037221770 cites W1993594227 @default.
• W2037221770 cites W1997928510 @default.
• W2037221770 cites W2017856888 @default.
• W2037221770 cites W2019006921 @default.
• W2037221770 cites W2019607817 @default.
• W2037221770 cites W2028737950 @default.
• W2037221770 cites W2031467322 @default.
• W2037221770 cites W2043215134 @default.
• W2037221770 cites W2049834126 @default.
• W2037221770 cites W2055263348 @default.
• W2037221770 cites W2088895925 @default.
• W2037221770 cites W2095826876 @default.
• W2037221770 cites W2097995306 @default.
• W2037221770 cites W2101653483 @default.
• W2037221770 cites W2101711321 @default.
• W2037221770 cites W2109513968 @default.
• W2037221770 cites W2114847324 @default.
• W2037221770 cites W2115188495 @default.
• W2037221770 cites W2115369775 @default.
• W2037221770 cites W2120041024 @default.
• W2037221770 cites W2123363005 @default.
• W2037221770 cites W2126163864 @default.
• W2037221770 cites W2128542677 @default.
• W2037221770 cites W2137723371 @default.
• W2037221770 cites W2143743735 @default.
• W2037221770 cites W2153017356 @default.
• W2037221770 cites W2154851015 @default.
• W2037221770 cites W2156078931 @default.
• W2037221770 cites W2160834915 @default.
• W2037221770 cites W2162383970 @default.
• W2037221770 cites W2164067249 @default.
• W2037221770 cites W2166262263 @default.
• W2037221770 cites W2168143310 @default.
• W2037221770 cites W2170202192 @default.
• W2037221770 cites W4293241248 @default.
• W2037221770 cites W4317564115 @default.
• W2037221770 doi "https://doi.org/10.1097/coc.0b013e318287bbae" @default.
• W2037221770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25616203" @default.
• W2037221770 hasPublicationYear "2015" @default.
• W2037221770 type Work @default.
• W2037221770 sameAs 2037221770 @default.
• W2037221770 citedByCount "32" @default.
• W2037221770 countsByYear W20372217702015 @default.
• W2037221770 countsByYear W20372217702016 @default.
• W2037221770 countsByYear W20372217702017 @default.
• W2037221770 countsByYear W20372217702018 @default.
• W2037221770 countsByYear W20372217702019 @default.
• W2037221770 countsByYear W20372217702020 @default.
• W2037221770 countsByYear W20372217702021 @default.
• W2037221770 countsByYear W20372217702022 @default.
• W2037221770 countsByYear W20372217702023 @default.
• W2037221770 crossrefType "journal-article" @default.
• W2037221770 hasAuthorship W2037221770A5005150991 @default.
• W2037221770 hasAuthorship W2037221770A5019015178 @default.
• W2037221770 hasAuthorship W2037221770A5028592995 @default.
• W2037221770 hasAuthorship W2037221770A5060495866 @default.
• W2037221770 hasAuthorship W2037221770A5073111231 @default.
• W2037221770 hasAuthorship W2037221770A5078388888 @default.
• W2037221770 hasAuthorship W2037221770A5088351796 @default.
• W2037221770 hasConcept C126322002 @default.
• W2037221770 hasConcept C141071460 @default.
• W2037221770 hasConcept C143998085 @default.
• W2037221770 hasConcept C197934379 @default.
• W2037221770 hasConcept C203092338 @default.
• W2037221770 hasConcept C2776694085 @default.
• W2037221770 hasConcept C2777292972 @default.
• W2037221770 hasConcept C2777802072 @default.
• W2037221770 hasConcept C2780739268 @default.
• W2037221770 hasConcept C2781413609 @default.
• W2037221770 hasConcept C29730261 @default.
• W2037221770 hasConcept C31760486 @default.
• W2037221770 hasConcept C535046627 @default.
• W2037221770 hasConcept C71924100 @default.
• W2037221770 hasConcept C90924648 @default.
• W2037221770 hasConceptScore W2037221770C126322002 @default.

• next